Research
Cancer and the development of metastases
One of the core competencies of simfo GmbH is research on the development of cancer and the development of metastases.
Cancer cells (CETCs/CTCs) can reach other areas of the body via the bloodstream and develop metastases there. Based on the maintrac® method, procedures are being developed that are contributing to a better understanding of metastatic processes.
Furthermore, simfo GmbH supports pharmaceutical manufacturers in the early phases of drug development by providing individual in vitro assays. The focus here is on evaluating the effectiveness of the medication. This can be done by directly testing the effectiveness on circulating tumour cells, for example, or by developing customised assays.
Diagnostics carried out with the study
In the contract research, problems are precisely pinpointed with the sponsor, the state of the art in science and technology is researched in detail and, based on this, approaches to solutions are worked out and implemented.
Our cooperation is based on partnership. Intensive dialogue between the researchers is encouraged and welcomed
Contract research
The development of an increase or decrease in CETCs could represent an endpoint for an oncological drug study. Thus, early indications of the outcome of the study may emerge and suitable measures may be taken.
The development of an increase or decrease in CETCs could represent an endpoint for an oncological drug study. Thus, early indications of the outcome of the study may emerge and suitable measures may be taken.
Training
simfo GmbH regularly offers training on maintrac® and thrombotrac in Bayreuth for doctors and medical professionals. You can find further information on training here
